Molecular dynamics simulation of human LOX-1 provides an explanation for the lack of OxLDL binding to the Trp150Ala mutant

Department of Biology and Center of Biostatistics and Bioinformatics, University of Rome Tor Vergata, Via della Ricerca Scientifica, Rome, Italy, 00133.
BMC Structural Biology (Impact Factor: 1.18). 02/2007; 7(1):73. DOI: 10.1186/1472-6807-7-73
Source: PubMed


Dimeric lectin-like oxidized low-density lipoprotein receptor-1 LOX-1 is the target receptor for oxidized low density lipoprotein in endothelial cells. In vivo assays revealed that in LOX-1 the basic spine arginine residues are important for binding, which is lost upon mutation of Trp150 with alanine. Molecular dynamics simulations of the wild-type LOX-1 and of the Trp150Ala mutant C-type lectin-like domains, have been carried out to gain insight into the severe inactivating effect.
The mutation does not alter the dimer stability, but a different dynamical behaviour differentiates the two proteins. As described by the residues fluctuation, the dynamic cross correlation map and the principal component analysis in the wild-type the two monomers display a symmetrical motion that is not observed in the mutant.
The symmetrical motion of monomers is completely damped by the structural rearrangement caused by the Trp150Ala mutation. An improper dynamical coupling of the monomers and different fluctuations of the basic spine residues are observed, with a consequent altered binding affinity.

7 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Per capire l’effetto di una distribuzione random di rugosità, abbiamo portato a termine la simulazione diretta del flusso turbolento in un canale con 3 differenti superfici rugose sulla parete inferiore: (I) una distribuzione di 10 prismi ad altezza random, (II) la stessa distribuzione di prismi rimuovendo i 4 più piccoli, (III) una distribuzione uniforme di prismi mantenendo la stessa area totale. L’attività di simulazione è stata svolta grazie alla collaborazione con il CASPUR, che ha messo a disposizione la propria infrastruttura di calcolo ad alte prestazioni.
    CASPUR ANNUAL REPORT, 2009 01/2009: chapter 11: pages 04; Consorzio interuniversitario per le Applicazioni di Supercalcolo Per Universita e Ricerca.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is a scavenger receptor that primarily binds and regulates oxidized low-density lipoprotein (LDL). Expression of LOX-1 is regulated by a feed-forward system stimulated by oxidized LDL (oxLDL), a major component of atherosclerosis. LOX-1 is a homodimer with a reactive backbone that can bind to a host of different ligands, including small molecules, and whole cells. LOX-1 is involved in many intercellular, intracellular, and molecular processes that are atherogenic. LOX-1 levels are elevated within atherosclerotic plaques and its expression is induced by proinflammatory cytokines. The ability of LOX-1 to bind many different ligands and control several atherogenic processes makes this receptor a likely vascular disease biomarker as well as an ideal choice for drug therapy aimed at preventing cardiovascular disease.
    Current Medicinal Chemistry 02/2009; 16(21):2641-52. DOI:10.2174/092986709788681994 · 3.85 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We assessed the ability of three widely used and freely available programs for side chain repacking to simulate the structural effects of single point mutations. The programs tested seem to produce sufficiently reliable predictions only when mutations involve residues characterized by limited flexibility. The change in size and/or polarity of the mutant side chain can affect the performances of the different programs. The correlation between the quality of predictions, exposure to solvent, and B-factors of the corresponding residues in crystal is also investigated. This analysis may provide non-experts with insights into what types of modelling protocols work best for such a problem as well as providing information to developers for improving their algorithms.
    Advances in Experimental Medicine and Biology 01/2010; 680:283-9. DOI:10.1007/978-1-4419-5913-3_32 · 1.96 Impact Factor
Show more

Preview (2 Sources)

7 Reads
Available from